Protocol Ledger

NCT05347095 · Phase III · ACTIVE NOT RECRUITING

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

Interventional Phase III clinical trial protocol NCT05347095 sponsored by Johnson & Johnson / Janssen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-27 Enrollment: 288 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05347095
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)288 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05347095
Protocol FieldVerified Registry Value
NCT IdentifierNCT05347095
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment288 participants (ACTUAL)
Registered Start Date2022-09-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI